Titan Medical Inc. (TMD.TO)
| Previous Close | 0.0700 |
| Open | 0.0650 |
| Bid | 0.0550 x 0 |
| Ask | 0.0600 x 0 |
| Day's Range | 0.0550 - 0.0650 |
| 52 Week Range | 0.0550 - 0.2700 |
| Volume | |
| Avg. Volume | 65,327 |
| Market Cap | 6.842M |
| Beta (5Y Monthly) | 1.98 |
| PE Ratio (TTM) | 0.75 |
| EPS (TTM) | 0.0800 |
| Earnings Date | Jun 07, 2024 - Jun 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireTitan Settles Contractual Dispute with Contract Manufacturer
TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that it has entered into a settlement agreement with a contract manufacturer (“Contractor”). Titan has reached a settlement agreement in connection with a dispute with the Contractor. Under the terms of the settlement, Titan has agreed to pay the Contractor an aggregate of US$2 million, with the final payment installment to be made on or before June 24, 2024. Upon receipt of the ful
- GlobeNewswire
Titan Medical Reports Fiscal Year 2023 Results
TORONTO, Ontario, March 29, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the fiscal year ended December 31, 2023. Recent Activities: On August 14, 2023, the Company announced the appointment of Dr. Daniel O’Brien, MD, MBA, Ph.D to its Board of Directors.On August 21, 2023, the Company announced a licensing agreement with Auris Health, Inc., a Johnson & Johnson MedTech Company.On October 18, 2023, the Company a
- GlobeNewswire
Titan Announces Q&A Session with Shareholders
TORONTO, Ontario, March 20, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that management will host a webcast Q&A session on March 27, 2024 at 1:00 p.m. ET in connection with the merger agreement entered into by Titan with Conavi Medical Inc. (“Conavi”), which was announced by press release issued on March 18, 2024. Titan will provide prepared remarks followed by a Q&A session. Paul Cataford, Interim President and CEO and Chien Huang, Chief Financial Offi
